ALPINE: Zanubrutinib in Relapsed/Refractory CLL and SLL

Mark Geyer, MD, and Yannis K. Valtis, MD, discussed real-world findings on the incidence, prevention, and management of tumor lysis syndrome in patients with CLL treated with venetoclax.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Acalabrutinib and zanubrutinib showed longer median TTD and TTNT compared to ibrutinib in CLL/SLL patients. Cardiovascular adverse effects were less frequent with acalabrutinib and zanubrutinib than with ibrutinib.

During a Case-Based Roundtable® event, Joanna M. Rhodes, MD, MSCE, discussed issues related to toxicity and dose modification in treating patients with Hodgkin lymphoma.